Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
After co-culture with TC cell lines, TC-induced macrophages showed significantly increased production of cytokines in both patients and controls, especially after co-culture with a PTEN-deficient TC cell line; these effects were abolished after use of rapamycin or a lactate transport blocker.
|
30670777 |
2019 |
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our data define a novel mechanism of PI3K/AKT hyperactivation and outline a regulatory role for miR-146b in suppressing PTEN expression, a frequent observation in thyroid cancer.
|
29353884 |
2018 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Sequencing of tumor tissue revealed a second hit in PTEN in the thyroid carcinoma and VC, confirmed by a PTEN loss and activation of the PI3K/AKT pathway in immunohistochemistry.
|
30111295 |
2018 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTEN knockdown in thyroid cancer cell lines stabilized intracellular NIS protein by promoting an interaction with NIS-LARG (leukemia-associated RhoA guanine exchange factor).
|
30217930 |
2018 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mouse models of sporadic thyroid cancer derived from BRAFV600E alone or in combination with PTEN haploinsufficiency under physiologic TSH levels.
|
30086162 |
2018 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PPFP thyroid cancers have increased activation of AKT, and mice with thyroid-specific expression of PPFP combined with thyroid-specific loss of PTEN (a negative regulator of AKT) develop thyroid cancer.
|
29420754 |
2018 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The latter could explain the clinically observed decrease in thyroid cancer prevalence in patients with co-existent PTEN mutations and SDHx variants.
|
28164237 |
2017 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
At the present time, no study has been undertaken to consider thyroid cancer treatment via FOXOs and PTEN targeting.
|
26597586 |
2016 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in the PTEN gene, which cause Cowden syndrome, are known to be one of the genetic factors for primary thyroid and breast cancers; however, PTEN mutations are found in only a small subset of research participants with non-syndrome breast and thyroid cancers.
|
26699384 |
2016 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
HMGB1-Induced Cross Talk between PTEN and miRs 221/222 in Thyroid Cancer.
|
26106610 |
2015 |
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We show that SRC inhibition could rescue SDHD dysfunction-induced cellular phenotype and tumorigenesis only when wild-type PTEN is expressed, in thyroid cancer lines.
|
25149476 |
2015 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutations in BRAF, NRAS, KRAS and PTEN, that are known to be involved in thyroid cancer biology, were detected in seven FNA samples.
|
24834793 |
2015 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Once a germline PTEN mutation is found, and a diagnosis of phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome made, the clinical outlook broadens to include higher lifetime risks for multiple cancers, beginning in childhood with thyroid cancer.
|
25916396 |
2015 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Interestingly, KLLN-associated risk of thyroid cancer appears to be gender and PTEN status dependent.
|
25669429 |
2015 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline variants in SDHB/C/D (SDHx) genes account for subsets of CS/CS-like cases, conferring a higher risk of breast and thyroid cancers over those with only germline PTEN mutations.
|
25694510 |
2015 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Strong correlations (0.68 ≤ r ≤ 1.0) were observed between PIK3C3 and PIM3 in breast cancer, between PIK3C3 and PTEN in breast and ovary cancers, and between PIM3 and PTEN in breast, kidney, liver, and thyroid cancers during disease progression, implicating that the correlations for cancer network gene expressions could serve as a supplement to current clinical biomarkers, such as cancer antigens, for early cancer diagnosis.
|
24818135 |
2014 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This was in contrast to patients with PTEN(mut+) who had thyroid cancer (0/39).
|
24712574 |
2014 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Notably, individuals with SDH(var+) alone had the highest thyroid cancer prevalence (24/47) compared with PTEN(mut+) patients (27/105, P = 0.002) or PTEN(mut+)/SDH(var+) carriers (6/22, P = 0.038).
|
21979946 |
2012 |
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our study shows that low blood PTEN protein expression could serve as a screening molecular correlate to predict for germline PTEN mutation in CS and CS-like presentations of thyroid cancer.
|
23066114 |
2012 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A total of 32 of 225 PTEN mutation+ patients (14%) had thyroid cancer: 52% papillary, 28% follicular-variant papillary, 14% follicular, and 6% anaplastic.
|
23158187 |
2012 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Children presenting with thyroid cancer should be tested for PTEN mutations.
|
21956414 |
2011 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline phosphatase and tensin homolog (PTEN) mutations cause Cowden syndrome (CS), associated with breast and thyroid cancers.
|
20600018 |
2010 |
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recent novel and promising findings include additional abnormalities in key pathways associated with thyroid tumorigenesis (RET-Ras-BRAF-MEK; RET-beta-cateinin; TRK-PI3K-AKT; and MDM-p53-PTEN), single-nucleotide polymorphisms associated with thyroid cancer susceptibility, epigenetic silencing, alternative splicing, and gene expression abnormalities.
|
19907326 |
2010 |
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Because in most of the thyroid carcinomas, DeltaNp73alpha is upregulated, whereas PTEN expression down regulated, we investigated whether DeltaNp73alpha may influence PTEN expression in this cell model.
|
19173293 |
2009 |
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We show here that adenosine triphosphate (ATP) regulates PTEN subcellular localization in a variety of different cancer cell lines, including those derived from breast, colon and thyroid carcinomas.
|
18579579 |
2008 |